Dennis Lyu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dennis Lyu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Michael P. Combs
University of Michigan Medical Center , Ann Arbor, MI
3 shared publications - Kevin M. Chan
Department of Medicine, Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI, USA
2 shared publications Aaron M. Williams
Department of Thoracic Surgery Vanderbilt University Medical Center Nashville Tennessee USA
1 shared publicationAdam Cochrane
Department of Pharmacy, Inova Fairfax Hospital, Falls Church, Virginia
1 shared publication- Aidan Patrick McLinden
Emory University School of Medicine
1 shared publication Allan R. Glanville
The Lung Transplant Unit, St. Vincent's Hospital, Sydney, New South Wales, Australia
1 shared publication
Latest Publications
- 19 March 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (3) , e70135
Use of Normothermic Regional Perfusion in Circulatory Death Donors for Lung Transplantation in the United States
Introduction: Use of normothermic regional perfusion (NRP) to recover donation after circulatory death (DCD) organs demonstrates increased heart utilization with favorable outcomes. Conversely, DCD lung allograft use when NRP was employed remains controversial. This is a contemporary analysis of DCD lung recipient outcomes in which NRP was used.Methods: Utilizing the STAR‐OPTN database, all adult DCD lung recipients in the United States between January 1, 2020, and June 30, 2024 were identified. NRP use was defined if the time between donor death and aortic clamp time was greater than 30 min. Recipient outcomes, including 30‐, 60‐, and 90‐day mortality, grade‐3 primary graft dysfunction (PGD), and postoperative length of stay were compared using multivariable logistic regression controlling for donor and recipient covariates. Survival analysis was performed using Cox proportional hazard modeling.Results: Of 987 DCD lung transplants, 92 (9.4%) utilized NRP. There were no differences in recipient characteristics between direct recovery and NRP cohorts. No difference in 30‐, 60‐, or 90‐day mortality, grade‐3 PGD, or length of stay was found between cohorts. 12‐month survival was equivalent.Conclusions: Outcomes between NRP lung recipients were equivalent to DCD direct recovery recipients. Thus, donor lungs may be considered for transplantation following NRP donation procedures.
- 19 March 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (3) , e70135
Use of Normothermic Regional Perfusion in Circulatory Death Donors for Lung Transplantation in the United States
Introduction: Use of normothermic regional perfusion (NRP) to recover donation after circulatory death (DCD) organs demonstrates increased heart utilization with favorable outcomes. Conversely, DCD lung allograft use when NRP was employed remains controversial. This is a contemporary analysis of DCD lung recipient outcomes in which NRP was used.Methods: Utilizing the STAR‐OPTN database, all adult DCD lung recipients in the United States between January 1, 2020, and June 30, 2024 were identified. NRP use was defined if the time between donor death and aortic clamp time was greater than 30 min. Recipient outcomes, including 30‐, 60‐, and 90‐day mortality, grade‐3 primary graft dysfunction (PGD), and postoperative length of stay were compared using multivariable logistic regression controlling for donor and recipient covariates. Survival analysis was performed using Cox proportional hazard modeling.Results: Of 987 DCD lung transplants, 92 (9.4%) utilized NRP. There were no differences in recipient characteristics between direct recovery and NRP cohorts. No difference in 30‐, 60‐, or 90‐day mortality, grade‐3 PGD, or length of stay was found between cohorts. 12‐month survival was equivalent.Conclusions: Outcomes between NRP lung recipients were equivalent to DCD direct recovery recipients. Thus, donor lungs may be considered for transplantation following NRP donation procedures.
- 28 May 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (10) , 1425-1436
Lung transplantation for lung cancer: A systematic review of the literature
- 28 May 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (10) , 1425-1436
Lung transplantation for lung cancer: A systematic review of the literature
- 26 November 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (3) , 317-326
The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation
- 26 November 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (3) , 317-326
The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation
- 1 February 2022
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 19 (2) , 335-338
Pretransplant Antifibrotic Therapy Is Associated with Resolution of Primary Graft Dysfunction
- 1 February 2022
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 19 (2) , 335-338
Pretransplant Antifibrotic Therapy Is Associated with Resolution of Primary Graft Dysfunction
- Open Access
- 10 November 2021
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 22, e934054-1-e934054-6
Use of Argatroban in Donor Lung Procurement: A Case Report
Objective: Unusual setting of medical care Background: Heparin-induced thrombocytopenia (HIT) is an immunological response to heparin exposure that predisposes patients to hypercoagulable reactions with subsequent heparin administration. Traditionally, heparin is the standard anticoagulant used during organ procurement to prevent clot formation in grafts. This creates a problem in donors or recipients that develop HIT as they are at risk of developing life-threatening coagulopathy. This raises the question of how to use alternative anticoagulation therapies, such as argatroban, that provide rapid-onset prophylaxis by reversibly inhibiting thrombin. Additionally, there are few studies that have assessed how recipients of multiorgan donors treated with argatroban do post-operatively. Case Report: In this report, we discuss the procurement protocol and hospital course of a lung transplant recipient who received a graft treated with argatroban due to a HIT-positive liver recipient. The post-operative course for our patient was uneventful, with improved lung function and no complications attributable to argatroban use. Further, none of the 4 other recipients who received organs from the same donor experienced graft dysfunctions secondary to coagulopathy, including the HIT-positive liver recipient. Conclusions: The ultimate success of grafts without thromboembolic complications suggests the use of argatroban in multiorgan procurement in the setting of a HIT-positive recipient is safe and effective. This case report highlights an alternative to the traditional process of organ procurement with heparin, in which patients at risk of coagulopathies secondary to HIT are able to receive organs when traditional protocols would otherwise be prohibitive.
- 10 November 2021
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 22, e934054-1-e934054-6
Open AccessUse of Argatroban in Donor Lung Procurement: A Case Report
Objective: Unusual setting of medical care Background: Heparin-induced thrombocytopenia (HIT) is an immunological response to heparin exposure that predisposes patients to hypercoagulable reactions with subsequent heparin administration. Traditionally, heparin is the standard anticoagulant used during organ procurement to prevent clot formation in grafts. This creates a problem in donors or recipients that develop HIT as they are at risk of developing life-threatening coagulopathy. This raises the question of how to use alternative anticoagulation therapies, such as argatroban, that provide rapid-onset prophylaxis by reversibly inhibiting thrombin. Additionally, there are few studies that have assessed how recipients of multiorgan donors treated with argatroban do post-operatively. Case Report: In this report, we discuss the procurement protocol and hospital course of a lung transplant recipient who received a graft treated with argatroban due to a HIT-positive liver recipient. The post-operative course for our patient was uneventful, with improved lung function and no complications attributable to argatroban use. Further, none of the 4 other recipients who received organs from the same donor experienced graft dysfunctions secondary to coagulopathy, including the HIT-positive liver recipient. Conclusions: The ultimate success of grafts without thromboembolic complications suggests the use of argatroban in multiorgan procurement in the setting of a HIT-positive recipient is safe and effective. This case report highlights an alternative to the traditional process of organ procurement with heparin, in which patients at risk of coagulopathies secondary to HIT are able to receive organs when traditional protocols would otherwise be prohibitive.
- 1 November 2021
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 40 (11) , 1279-1300
ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements
- 1 November 2021
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 40 (11) , 1279-1300
ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements